AGP
REGN icon

Aspire Growth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Aspire Growth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$484K Hold
626
– – 0.33% 68
2025
Q4 		$483K Buy
626
+1
+0.2% +$679 0.34% 69
2025
Q3 		$351K Buy
625
+1
+0.2% +$565 0.26% 85
2025
Q2 		$328K Buy
624
+1
+0.2% +$558 0.27% 86
2025
Q1 		$349K Buy
623
+32
+5% +$22K 0.31% 77
2024
Q4 		$421K Buy
+591
New +$496K 0.41% 61

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Aspire Growth Partners's REGN Position: Q1 2026 in Review

Aspire Growth Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 626 shares worth $484K. The position accounts for 0.33% of the portfolio, ranked #68.

Aspire Growth Partners first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Aspire Growth Partners held 626 shares of Regeneron Pharmaceuticals worth $484K as of Q1 2026.
  • Aspire Growth Partners left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.33% of Aspire Growth Partners's portfolio in Q1 2026, its #68 holding.
  • Aspire Growth Partners first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Aspire Growth Partners's 13F filing for Q1 2026, filed 17 Apr 2026.